Hang Seng Medical ETF (513060) call back to the car opportunity, Teng Shengbo Pharmaceutical -B rose by more than 20%

In the morning, Hang Seng Medical ETF (513060) shocked. Among the ingredients stocks, the pharmaceutical sector strengthened, Tengsheng Bo Pharmaceutical -B rose more than 20%, minimally invasive robot-B rose more than 6%, three-leaf grass biological-B rose more than 4%, pioneering pharmaceutical-B rose more than 3%, first voice, first voice Pharmaceuticals, Green Leaf Pharmaceutical, China Resources Pharmaceutical and other stocks have risen. As of press time, Hang Seng Medical ETF (513060) transaction turnover exceeded 3. billion, and the net inflow of nearly 60 days exceeded 3.5 billion.

On the news, on July 8, 2022, the relevant departments issued an announcement of the "Regulations on the Management of Vaccine Production and Circulation". According to the characteristics of vaccine product characteristics and vaccine regulatory requirements, the production and circulation management activities of vaccines were regulated in accordance with the law. The "Regulations" pointed out that the state implements a strict admission system for vaccine production and strictly controls new vaccine manufacturers. The newly opened vaccine manufacturers should also meet the relevant policies of the national vaccine industry authorities in addition to the running conditions of the vaccine manufacturers. The holder should have the vaccine production capacity.

Open source securities stated that the state implements a strict admission system for vaccine production and strictly controls the newly opened vaccine manufacturers. This regulation is expected to promote the further development of existing vaccine companies. At the same time, it is expected to promote the research and development, production and sales of multi -price vaccines to carry out multi -price vaccines.

- END -